↓ Skip to main content

Dove Medical Press

Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity

Overview of attention for article published in Breast cancer targets and therapy, February 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
41 Mendeley
Title
Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity
Published in
Breast cancer targets and therapy, February 2017
DOI 10.2147/bctt.s130838
Pubmed ID
Authors

Manpreet Sambi, Sabah Haq, Vanessa Samuel, Bessi Qorri, Fiona Haxho, Kelli Hill, William Harless, Myron R Szewczuk

Abstract

One of the primary challenges in developing effective therapies for malignant tumors is the specific targeting of a heterogeneous cancer cell population within the tumor. The cancerous tumor is made up of a variety of distinct cells with specialized receptors and proteins that could potentially be viable targets for drugs. In addition, the diverse signals from the local microenvironment may also contribute to the induction of tumor growth and metastasis. Collectively, these factors must be strategically studied and targeted in order to develop an effective treatment protocol. Targeted multimodal approaches need to be strategically studied in order to develop a treatment protocol that is successful in controlling tumor growth and preventing metastatic burden. Breast cancer, in particular, presents a unique problem because of the variety of subtypes of cancer that can arise and the multiple drug targets that could be exploited. For example, the tumor stage and subtypes often dictate the appropriate treatment regimen. Alternate multimodal therapies should consider the importance of time-dependent drug administration, as well as targeting the local and systemic tumor environment. Many reviews and papers have briefly touched on the clinical implications of this cellular heterogeneity; however, there has been very little discussion on the development of study models that reflect this diversity and on multimodal therapies that could target these subpopulations. Here, we summarize the current understanding of the origins of intratumoral heterogeneity in breast cancer subtypes, and its implications for tumor progression, metastatic potential, and treatment regimens. We also discuss the advantages and disadvantages of utilizing specific breast cancer models for research, including in vitro monolayer systems and three-dimensional mammospheres, as well as in vivo murine models that may have the capacity to encompass this heterogeneity. Lastly, we summarize some of the current advancements in the development of multitarget therapeutics that have shown promising results in clinical and preclinical studies when used alone or in combination with traditional regimens of surgery, chemotherapy, and/or radiation.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 41 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 22%
Student > Bachelor 6 15%
Researcher 5 12%
Student > Master 5 12%
Student > Doctoral Student 2 5%
Other 6 15%
Unknown 8 20%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 7 17%
Medicine and Dentistry 6 15%
Agricultural and Biological Sciences 4 10%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Chemistry 3 7%
Other 7 17%
Unknown 11 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 March 2017.
All research outputs
#15,523,434
of 25,382,440 outputs
Outputs from Breast cancer targets and therapy
#143
of 324 outputs
Outputs of similar age
#232,528
of 424,972 outputs
Outputs of similar age from Breast cancer targets and therapy
#8
of 20 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 324 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 424,972 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.